The use of interspinous distraction implants to increase spinal canal crosssectional area and thus reduce spinal claudication symptoms has gained in popularity during the past decade. The first of these devices approved for sale in the U.S., is the X-Stop spacer (St. Francis Medical Technologies, Inc., Alameda, CA). The X-stop was approved despite a 50% clinical failure rate in the clinical trial that were reviewed, due primarily to the low morbidity of the original procedure and the absence of a less invasive clinically effective alternative. Subsequent studies have demonstrated variable outcomes and there is only one prospective four year outcome study published.
Is Periprostatic Nerve Block a Gold Standard in Case of
This prospective study evaluated outcomes in 29 consecutive stenotic patients treated with this device. 'Exclusion criteria were radicular motor deficit, conus/cauda-lesion, manifest osteoporosis, spondylolisthesis more than grade 1 at the stenotic level and scoliosis with a Cobb angle more than 20°, and patients with symptoms unresponsive to postural alteration.' Forty-six patients were originally enrolled in the study, but for a variety of reasons (e.g. 5 patients did not achieve the minimum postoperative period of 24 months) were not included in the evaluation.
On the whole, lumbar pain decreased by 33% and leg pain by 64% using VAS outcome data. A little less than half the patients (47%) treated were self-proclaimed to be very satisfied. "According to the criteria stated earlier, clinical success could be achieved in 36.4% (n = 16) of the [enrolled 46 originally enrolled, two were lost to f/u] patients. Fourteen of the patients, including the 2 patients who had the implant removed and were contacted by phone, had to undergo revision surgery. … Mean time until implant removal was 15.4 _ 18.4 months."
